Depomed Announces US Food and Drug Administration Approval of GRALISE(TM) (gabapentin) Once-Daily Tablets for Treatment of Po

MENLO PARK, Calif., Jan. 28, 2011 (GLOBE NEWSWIRE) — Depomed, Inc. (Nasdaq:DEPO) today announced that US FDA has approved GRALISE™ (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia (PHN), which is pain following healing of the rash associated with shingles. GRALISE was developed by Depomed under the code name DM-1796 and is licensed to Abbott [...] http://bit.ly/ghXnfY